Trial
NCT02612194
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Wake Forest University Health Sciences
Collaborators
Pfizer
Condition
Urinary Bladder Neoplasms
Intervention
Crizotinib
Why stopped
Study closed to accrual due to low accrual numbers.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-03